Mutations in EGFR or other kinases, which are crucial components in the activation of the classical mitogen-activated protein (MAP) kinase cascade, are prime examples of how soluble ligands with less mutability are associated with important downstream signaling pathways—and through which mutations can cause cancer. The gene discussed is EGFR; the disease is cancer.